251 related articles for article (PubMed ID: 21392167)
1. Cytokine signatures of transformed B cells with distinct Epstein-Barr virus latencies as a potential diagnostic tool for B cell lymphoma.
Miyauchi K; Urano E; Yoshiyama H; Komano J
Cancer Sci; 2011 Jun; 102(6):1236-41. PubMed ID: 21392167
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of tumor necrosis factor-alpha gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome.
Lay JD; Tsao CJ; Chen JY; Kadin ME; Su IJ
J Clin Invest; 1997 Oct; 100(8):1969-79. PubMed ID: 9329960
[TBL] [Abstract][Full Text] [Related]
3. Histological characteristics of 21 Papua New Guinean children with high-grade B-cell lymphoma, which is frequently associated with EBV infection.
Nomura Y; Lavu EK; Muta K; Niino D; Takeshita M; Hirose S; Nakamura S; Yoshino T; Kikuchi M; Ohshima K
Pathol Int; 2008 Nov; 58(11):695-700. PubMed ID: 18844934
[TBL] [Abstract][Full Text] [Related]
4. Regulation of germ-line epsilon transcription and induction of epsilon switching in cloned EBV-transformed and malignant human B cell lines by cytokines and CD4+ T cells.
Gauchat JF; Gascan H; de Waal Malefyt R; de Vries JE
J Immunol; 1992 Apr; 148(7):2291-9. PubMed ID: 1347554
[TBL] [Abstract][Full Text] [Related]
5. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.
De Leo A; Arena G; Stecca C; Raciti M; Mattia E
Mol Cancer Res; 2011 Oct; 9(10):1346-55. PubMed ID: 21856773
[TBL] [Abstract][Full Text] [Related]
6. Lymphotoxin acts as an autocrine growth factor for Epstein-Barr virus-transformed B cells and differentiated Burkitt lymphoma cell lines.
Gibbons DL; Rowe M; Cope AP; Feldmann M; Brennan FM
Eur J Immunol; 1994 Aug; 24(8):1879-85. PubMed ID: 8056047
[TBL] [Abstract][Full Text] [Related]
7. Common and idiosyncratic patterns of cytokine gene expression by Epstein-Barr virus transformed human B cell lines.
Rochford R; Cannon MJ; Sabbe RE; Adusumilli K; Picchio G; Glynn JM; Noonan DJ; Mosier DE; Hobbs MV
Viral Immunol; 1997; 10(4):183-95. PubMed ID: 9473149
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus (EBV) and human hematopoietic cell lines: a review.
Tatsumi E
Hum Cell; 1992 Mar; 5(1):79-86. PubMed ID: 1329932
[TBL] [Abstract][Full Text] [Related]
9. Cytokine mediated induction of the major Epstein-Barr virus (EBV)-encoded transforming protein, LMP-1.
Kis LL; Takahara M; Nagy N; Klein G; Klein E
Immunol Lett; 2006 Apr; 104(1-2):83-8. PubMed ID: 16386314
[TBL] [Abstract][Full Text] [Related]
10. Human B-lymphoid cell lines.
Nilsson K
Hum Cell; 1992 Mar; 5(1):25-41. PubMed ID: 1329931
[TBL] [Abstract][Full Text] [Related]
11. Regulation of interleukin-1beta transcription by Epstein-Barr virus involves a number of latent proteins via their interaction with RBP.
Krauer KG; Belzer DK; Liaskou D; Buck M; Cross S; Honjo T; Sculley T
Virology; 1998 Dec; 252(2):418-30. PubMed ID: 9878621
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.
Leong IT; Fernandes BJ; Mock D
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):184-93. PubMed ID: 11505266
[TBL] [Abstract][Full Text] [Related]
13. Rheumatoid factors induce signaling from B cells, leading to Epstein-Barr virus and B-cell activation.
Yang L; Hakoda M; Iwabuchi K; Takeda T; Koike T; Kamatani N; Takada K
J Virol; 2004 Sep; 78(18):9918-23. PubMed ID: 15331725
[TBL] [Abstract][Full Text] [Related]
14. Production of the immunosuppressive cytokine interleukin-10 by Epstein-Barr-virus-expressing pyothorax-associated lymphoma: possible role in the development of overt lymphoma in immunocompetent hosts.
Kanno H; Naka N; Yasunaga Y; Iuchi K; Yamauchi S; Hashimoto M; Aozasa K
Am J Pathol; 1997 Jan; 150(1):349-57. PubMed ID: 9006350
[TBL] [Abstract][Full Text] [Related]
15. The distinction between Burkitt lymphoma and diffuse large B-Cell lymphoma with c-myc rearrangement.
Nakamura N; Nakamine H; Tamaru J; Nakamura S; Yoshino T; Ohshima K; Abe M
Mod Pathol; 2002 Jul; 15(7):771-6. PubMed ID: 12118116
[TBL] [Abstract][Full Text] [Related]
16. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus: 40 years on.
Young LS; Rickinson AB
Nat Rev Cancer; 2004 Oct; 4(10):757-68. PubMed ID: 15510157
[TBL] [Abstract][Full Text] [Related]
18. T cell recognition of Epstein-Barr virus associated lymphomas.
Rickinson AB; Murray RJ; Brooks J; Griffin H; Moss DJ; Masucci MG
Cancer Surv; 1992; 13():53-80. PubMed ID: 1330300
[TBL] [Abstract][Full Text] [Related]
19. Regulation of CD44-hyaluronan interactions in Burkitt's lymphoma and Epstein-Barr virus-transformed lymphoblastoid B cells by PMA and interleukin-4.
Kryworuchko M; Gee K; Diaz-Mitoma F; Kumar A
Cell Immunol; 1999 May; 194(1):54-66. PubMed ID: 10357881
[TBL] [Abstract][Full Text] [Related]
20. Restoration of the LFA-3 adhesion pathway in Burkitt's lymphoma cells using an LFA-3 recombinant vaccinia virus: consequences for T cell recognition.
Griffin H; Rowe M; Murray R; Brooks J; Rickinson A
Eur J Immunol; 1992 Jul; 22(7):1741-8. PubMed ID: 1378014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
